Conor’s COSTAR II
This article was originally published in The Gray Sheet
Executive Summary
Firm has completed enrollment of 1,700 patients in its U.S. non-inferiority pivotal study comparing Costar paclitaxel-eluting stent to Boston Scientific's Taxus Express to treat de novo lesions. Conor modified the trial protocol in February due to slower-than-expected enrollment of the multi- versus single-vessel arm (1"The Gray Sheet" Feb. 20, 2006, p. 7). Assuming favorable results, Conor projects FDA approval for the DES in late 2007 or early 2008...